Navamedic

Share Issue/Capital Change • Sep 22, 2025

Navamedic ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates

Navamedic ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates

Oslo, 22 September 2025: Reference is made to the stock exchange announcement

published by Navamedic ASA (the "Company") earlier today, 22 September 2025,

regarding the commencement of the subscription period in the partly underwritten

rights issue of up to 6,046,511 new shares in the Company, at a subscription

price of NOK 21.50 per share (the "Rights Issue"). As part of this process,

tradable subscription rights have been allocated to certain primary insiders,

and certain close associates of primary insiders, of the Company:

Soleglad Invest AS, a company closely associated with Kathrine Elisabeth Gamborg

Andreassen, CEO of the Company, has on 22 September 2025 received 264,165

subscription rights in the Company with no price payable.

Lars Hjarrand, CFO of the Company, has on 22 September 2025 received 121,829

subscription rights in the Company with no price payable.

Jurs AS, a company close associated with Morten Jurs, member of the Board of

Directors of the company has on 22 September 2025 received 7,851 subscription

rights in the Company with no price payable.

Astrid T. Bratvedt, Chief Scientific Officer of the Company, has on 22 September

2025 received 684 subscription rights in the Company with no price payable.

Tranbergkollen Invest AS, a company closely associated with, Astrid T. Bratvedt,

Chief Scientific Officer of the Company, has on 22 September 2025 received

205,398 subscription rights in the Company with no price payable.

Ole Henrik Eriksen, Chief Business Development Officer of the Company, has on 22

September 2025 received 25,674 subscription rights in the Company with no price

payable.

Leikerane AS, a company closely associated with Ole Henrik Eriksen, Chief

Business Development Officer of the Company, has on 22 September 2025 received

171,165 subscription rights in the Company with no price payable.

Karianne Femtehjell Olsen, Commercial Director CHC & Nutrition of the Company,

has on 22 September 2025 received 9,508 subscription rights in the Company with

no price payable.

Alexander Lidmejer, COO of the Company, has on 22 September 2025 received 22,981

subscription rights in the Company with no price payable.

Philip Slätis, Commercial Director RX & International, has on 22 September 2025

received 3,423 subscription rights in the Company with no price payable.

Jostein Davidsen, Chairman of the Board of the Company, has on 22 September 2025

received 17,116 subscription rights in the Company with no price payable.

Åsa Kornfeldt, member of the Board of Directors of the Company, has on 22

September 2025 received 1,362 subscription rights in the Company with no price

payable.

Edmèe Steenken, member of the Board of Directors of the Company, has on 22

September 2025 received 3,423 subscription rights in the Company with no price

payable.

Rune Wahl, member of the Board of Directors of the Company, has on 22 September

2025 received 20,539 subscription rights in the Company with no price payable.

Please see the attached notifications of trade for further information regarding

the primary insiders' and their close associates' receipt of tradable

subscription rights in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.